Harold Shlevin Sells 24,499 Shares of Galectin Therapeutics (NASDAQ:GALT) Stock

Galectin Therapeutics Inc. (NASDAQ:GALT) Director Harold Shlevin sold 24,499 shares of the firm’s stock in a transaction that occurred on Wednesday, December 17th. The stock was sold at an average price of $7.04, for a total value of $172,472.96. Following the sale, the director directly owned 6,500 shares of the company’s stock, valued at $45,760. This represents a 79.03% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link.

Galectin Therapeutics Price Performance

GALT stock opened at $4.38 on Friday. Galectin Therapeutics Inc. has a 12 month low of $0.73 and a 12 month high of $7.13. The firm’s 50-day moving average is $5.57 and its 200 day moving average is $4.19. The company has a market capitalization of $282.38 million, a PE ratio of -7.42 and a beta of 0.95.

Galectin Therapeutics (NASDAQ:GALT) last announced its quarterly earnings data on Friday, November 14th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.02). Sell-side analysts forecast that Galectin Therapeutics Inc. will post -0.73 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms have commented on GALT. Weiss Ratings reiterated a “sell (d-)” rating on shares of Galectin Therapeutics in a research note on Wednesday, October 8th. HC Wainwright boosted their price objective on shares of Galectin Therapeutics from $6.00 to $11.00 and gave the company a “buy” rating in a report on Wednesday. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $11.00.

More Galectin Therapeutics News

Here are the key news stories impacting Galectin Therapeutics this week:

• Positive Sentiment: FDA written response aligns with the company on the proposed patient population for a registration trial of belapectin and the company will pursue a follow‑up Type C meeting to finalize trial design; management says new biomarker data will be presented. This reduces some regulatory uncertainty for the lead program. Galectin Therapeutics Provides Regulatory Update
• Positive Sentiment: Galectin secured a $10M unsecured, convertible line of credit from its chairman and extended maturities on related notes, which management says funds operations into at least March 2027 — a near‑term liquidity buffer while belapectin development continues. Regulatory update & financing
• Neutral Sentiment: Technically, the stock recently crossed above its 200‑day moving average — a bullish technical sign for some traders, but not a fundamental change. Shares Cross Above 200-Day Moving Average
• Negative Sentiment: Significant insider selling: multiple insiders (CEO Joel Lewis, Director Harold H. Shlevin, CMO Khurram Jamil) sold large blocks of stock on Dec. 16–17 at prices in the $6.66–$7.06 range — and a major shareholder (Fund L.P. 10X) also sold ~30,681 shares. The concentrated selling likely pressured the share price despite the regulatory/financing news. Insider Selling: Galectin Therapeutics
• Negative Sentiment: While HC Wainwright maintained a Buy and raised its price target to $11 (from $6), analyst optimism can be slower to offset immediate selling pressure from insiders and short‑term traders. HC Wainwright maintains Buy, raises target

Hedge Funds Weigh In On Galectin Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the business. HighTower Advisors LLC boosted its holdings in shares of Galectin Therapeutics by 244.1% in the 1st quarter. HighTower Advisors LLC now owns 77,375 shares of the company’s stock valued at $94,000 after acquiring an additional 54,889 shares during the last quarter. Wealthspire Advisors LLC raised its holdings in shares of Galectin Therapeutics by 20.4% during the second quarter. Wealthspire Advisors LLC now owns 479,518 shares of the company’s stock worth $1,012,000 after purchasing an additional 81,144 shares during the last quarter. Truist Financial Corp acquired a new position in Galectin Therapeutics during the second quarter valued at $143,000. Geneos Wealth Management Inc. boosted its holdings in Galectin Therapeutics by 8.8% in the first quarter. Geneos Wealth Management Inc. now owns 423,235 shares of the company’s stock valued at $516,000 after purchasing an additional 34,300 shares during the last quarter. Finally, Stratos Wealth Partners LTD. boosted its holdings in Galectin Therapeutics by 17.8% in the second quarter. Stratos Wealth Partners LTD. now owns 60,750 shares of the company’s stock valued at $128,000 after purchasing an additional 9,200 shares during the last quarter. Institutional investors and hedge funds own 11.68% of the company’s stock.

Galectin Therapeutics Company Profile

Galectin Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel therapies that target galectin proteins, which are implicated in fibrotic, inflammatory and malignant diseases. The company’s lead product candidate, belapectin (formerly GR-MD-02), is a galectin-3 inhibitor being evaluated in Phase 2 clinical trials for nonalcoholic steatohepatitis (NASH) with cirrhosis. In addition to its core pipeline in fibrotic liver disease, Galectin Therapeutics continues to explore the potential of its galectin inhibitors in oncology and other indications driven by abnormal tissue remodeling.

Founded in 2000, the company is headquartered in Norcross, Georgia, where it oversees discovery research, preclinical studies and clinical trial coordination.